Evotec to Invest in Carrick Therapeutics

Evotec today announced that it will invest up to $6 million in Carrick’s latest funding round.
According to the press release:

“Carrick is building an innovative portfolio of first-in-class treatments that target multiple mechanisms of the most aggressive forms of cancer, and which will be tailored to an individual patient’s tumour. To support this mission Evotec will provide its full range of discovery and oncology services, through its discovery and pre-clinical platform. Carrick will progress multiple programmes through hit-to-lead and lead optimisation with the goal of delivering multiple development candidates.”

Evotec’s CEO, Werner Lanthaler, said:

“We are very excited to be part of creating and co-owning a next generation leading oncology company. Putting all Evotec’s tools that support innovation and capital efficiency at work will allow Carrick to very rapidly progress a first-in-class oncology pipeline.”

Read the full press release here.